From Self-sufficiency
Jump to: navigation, search
Systematic (IUPAC) name
1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-4-(ethylamino)piperidine-4- carboxamide
CAS Number 686344-29-6
ATC code none
Chemical data
Formula C25H25Cl2N7O
Molar mass 510.4[[Script error: No such module "String".]]
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Otenabant (CP-945,598) is a drug which acts as a potent and highly selective CB1 antagonist.[1] It was developed by Pfizer for the treatment of obesity,[2] but development for this application has been discontinued following the problems seen during clinical use of the similar drug rimonabant.[3]

See also


Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

  1. Kim, M.; Yun, H.; Kwak, H.; Kim, J.; Lee, J. (2008), "Design, chemical synthesis, and biological evaluation of novel triazolyl analogues of taranabant (MK-0364), a cannabinoid-1 receptor inverse agonist" (PDF), Tetrahedron, 64: 10802 – 10809, doi:10.1016/j.tet.2008.09.057 
  2. Woods SC. The endocannabinoid system: novel pathway for cardiometabolic Risk-factor reduction. Journal of the American Academy of Physician Assistants. 2007 Nov;Suppl Endocannabinoid:7-10. PMID 18047036
  3. http://www.pfizer.com